Ultimately, our aim is to develop personalized neuroimmune therapeutic strategies that actively impact the treatment outcomes of AD by targeting the interactions between RHBDF2, TNFRSF10B, and immune cells. The gene discussed is RHBDF2; the disease is Alzheimer disease.